What scientific specialization defines E.R.D.E.-AAK-Diagnostik GmbH’s long-term research and diagnostic focus?
The first 10 years of the laboratory focused on basic research of G-protein coupled receptors (GPCR), an important family of membrane proteins that transmit extracellular signals into cells. The GPCR superfamily includes several hundred receptors found in all human and animal tissues. In 2012, Robert J. Lefkowitz and Brian K. Kobilka received the Nobel Prize in Chemistry for elucidating the function of G protein-coupled receptors. They mediate the effects of various signalling molecules, such as hormones and neurotransmitters. GPCRs regulate nearly all bodily functions, controlling physiological processes and playing a central role in pathological conditions. They are primary targets for pharmacological therapies.
Using the alpha-1 adrenergic receptor as an example in an animal model, E.R.D.E.-AAK-Diagnostik GmbH demonstrated that the respective agonistic autoantibody reduces blood flow and decreases the number of intact blood vessels. This GPCR regulates myocardial contractile function and glucose metabolism.
7 tesla MRT of Rat Brain: Reduction of Blood Flow over a Period of 8 Months, with Ferrumoxytol
Immunostaining: Decrease in Intact Blood Vessels Within 8 Months
Another focus was the development of diagnostic tools. agAAB play a significant role in diseases, including DCM, myocarditis, hypertension, type 2 diabetes, dementia, transplant rejection, and post-COVID/post-vaccine conditions. These autoantibodies are associated with specific receptors, including α1, β1, β2, AT1, M2, and ET. Examination of agAAB status is crucial for personalized therapies.
Agonistic autoantibodies bind specifically to receptors found in various tissues. β-1 is in the heart, kidneys, and adipose tissue; β-2 is in the heart, lungs, and nerve cells. M-2 is in the heart and brainstem, α-1 is in the blood vessels and nerve tissue. AT-1 is in the vascular system, heart, kidneys, liver, and brain. ACE2 also serves as the entry point for viruses. PAR, a GPCR subgroup, is involved in inflammation, coagulation, and digestive processes.
Which clinical conditions are central to E.R.D.E.-AAK-Diagnostik GmbH’s translational research efforts?
Key Areas of Clinical Research Focus
The clinical work at E.R.D.E.-AAK-Diagnostik GmbH focused on agAAB’s involvement in Alzheimer’s, vascular dementia, and type 2 diabetes. A US patent was granted for the company’s Alzheimer’s research. Following immunoadsorption aimed at reducing circulating agonistic autoantibodies, cognitive function in Alzheimer’s patients remained stable over the long term, with results confirmed in multiple studies.
Cognitive Stabilization: Observation Period 12-18 Months / ADAS-Cog and MMSE
What findings has E.R.D.E.-AAK-Diagnostik GmbH observed in post-COVID and post-vaccine patients?
Post-COVID, Post-Vac, ME/CFS
Since 2021, numerous agAAB have been detected in patients with post-COVID and post-vaccine conditions. Immunoadsorption to remove agAAB has yielded highly satisfactory results, as these autoantibodies cannot be blocked or removed through medication and cannot be traded by other aphereses procedures.
In addition to scientific and diagnostic work, the company contributes to YouTube videos, podcasts, conference presentations, and continuing medical education for physicians.
Diagnostic Laboratory Info
What led E.R.D.E.-AAK-Diagnostik GmbH to be recognized among top diagnostic laboratory service providers?
A highly specialized focus on autoantibody diagnostics has positioned E.R.D.E.-AAK-Diagnostik GmbH as a distinctive name in Diagnostic Laboratory Services. The laboratory has spent more than 25 years researching and identifying agonistic autoantibodies, particularly those targeting G-protein-coupled receptors, which play a role in numerous chronic and post-viral conditions. Its ability to combine long-term scientific research with applied diagnostics has contributed to its recognition in Diagnostic Laboratory Services.
How does the company differentiate its approach to diagnostic laboratory services?
Scientific depth and functional testing define how the laboratory delivers Diagnostic Laboratory Services. It does not limit analysis to standard detection methods but uses multiple test systems to identify and functionally assess agonistic autoantibodies depending on the clinical question. This approach enables a more precise understanding of how these antibodies interact with cellular receptors, offering insights that extend beyond conventional laboratory testing.
How does E.R.D.E.-AAK-Diagnostik GmbH support healthcare professionals and patients?
Support within its Diagnostic Laboratory Services is structured around both testing and guidance. The laboratory offers serum testing services for various autoantibodies and provides interpretation support for results, helping connect findings to potential therapeutic pathways. When relevant, it also facilitates access to medical expertise for further consultation, ensuring that test outcomes translate into actionable insights.
What value do its diagnostic services bring to disease understanding and management?
Targeted identification of disease-related autoantibodies defines the value of its Diagnostic Laboratory Services. The laboratory’s work supports understanding of conditions such as post-COVID syndromes, cardiovascular disorders and neurodegenerative diseases by identifying underlying immune mechanisms. This enables more informed clinical decisions and contributes to personalized treatment considerations, particularly where conventional diagnostics may not provide sufficient clarity.
What role do expertise and research play in its services?
Long-term research expertise is central to the laboratory’s Diagnostic Laboratory Services. Its scientific work includes published studies and patented approaches related to autoantibody-associated conditions, including dementia research. This foundation allows the company to continuously refine diagnostic techniques and expand its understanding of disease mechanisms, ensuring that its services remain grounded in evidence and innovation.
Why is E.R.D.E.-AAK-Diagnostik GmbH relevant to current diagnostic needs?
Growing interest in immune-mediated and post-viral conditions has increased demand for specialized testing, and E.R.D.E.-AAK-Diagnostik GmbH addresses this through its Diagnostic Laboratory Services. Its focus on autoantibodies linked to conditions such as ME/CFS and post-COVID syndromes aligns with emerging clinical priorities. By offering targeted, research-driven diagnostics, the laboratory remains closely aligned with evolving healthcare needs.
